According to Johnson & Johnson’s recommendation to suspend the use of vaccines, the European Commission stated that ensuring the safety of all biological agents is of utmost importance.
Brussels, Belgium (Europa Press). -Health Commissioner Stella Kyriakides said after learning that the release of Jensen’s vaccine against covid-19 was postponed, it was “necessary” to ensure its safety and reminded the European Medicines Agency (EMA) We have been evaluating thrombotic events found in people who received this vaccine for a few days in the United States.
He wrote on the social network Twitter: “Today, the development of Johnson & Johnson (Jensen & Sons) vaccines in the United States is being closely monitored by the European Union and its pharmacovigilance agencies, and maintains open contact with the FDA and other international regulatory agencies.”
Cyprus added: “The company has suspended its (vaccine) launch in the European Union. The safety of vaccines is always of the utmost importance.”
Jensen’s delay in delivering vaccines to member states threatens the European Union’s vaccination program. Community authorities placed great hopes in the second quarter of this year, partly because the serum developed by Johnson & Johnson Pharmaceuticals entered the European Union and only required one injection to reach the scheduled timetable.
A few hours before the Kyriakides news, Janssen announced that it would stop the release of the vaccine against covid-19 in Europe. Previously, the United States had been suspended due to 6 cases of thrombosis in the vaccinated population.
However, compared with the 6.8 million doses of the above-mentioned pharmaceutical companies administered nationwide, these six cases accounted for a low proportion. In all cases, these were women between the ages of 18 and 48, who developed symptoms between 6 and 13 days after vaccination.
The company explained in a statement: “We have reviewed these cases with European health authorities. We have decided to proactively postpone the launch of our vaccine in Europe.”
Just four days ago, the EMA announced that the Pharmacovigilance Risk Assessment Committee (PRAC) was investigating four serious thromboembolic events in people receiving the Covid-19 vaccine developed by Jannsen.